8 June, 2023 | Online
13:00-14:00 CEST

Chairs: Prof. Dr Christoph Lange (Borstel, Germany); Prof. Dr Raquel Duarte (Porto, Portugal)
Speakers: Prof. Stephen Henry Gillespie (St. Andrews, United Kingdom), Mr. Niklas Köhler (Lübeck, Germany), Ms. Jodie Schildkraut (Nijmegen, Netherlands)

Educational aims

Overall, the aim is to enhance participants' knowledge of biomarkers, surrogate markers, and treatment monitoring tools for tuberculosis clinical trials, with a view to improving diagnosis and treatment outcomes.

Topics

• Definitions of biomarkers and surrogate markers as they relate to tuberculosis clinical trials;
• Discussion about UNITE4TB's TPP and the current state of the art.
• Prediction

Target audience:

• Healthcare Professionals
• Decision Makers
• Policy Makers
• Researchers
• TB Community

Format

Webinar will be divided into 2 parts (of approximately 30 mins. each):
? For the first 30 minutes, the speaker Stephen Gillespie will debate the pros and cons of rolling out new drugs and treatment regimens for TB without diagnostic capacities.
? The second half of the webinar will be filled with an open discussion, moderated by Raquel Duarte and Christoph Lange, giving the opportunity to the participants of sharing perspectives on the topics presented and/or posing questions to the speaker.

Learning outcomes

At the end of this talk, participants will be able to:

• Define the terms biomarker, surrogate marker, and surrogate
• Using these definitions explore the currently available tuberculosis diagnostic tests
• Describe the objectives, constraints and opportunities of monitoring treatment response in clinical trials
• Describe the "soon to be deployed" treatment monitoring tools
• Describe plans for future treatment monitoring tools for clinical trials (the UNITE4TB target product profile)